Jeffrey S. Parkin

Array ( [id] => 12858052 [patent_doc_number] => 20180177858 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-06-28 [patent_title] => INVOLUCRIN-DRIVEN RETROVIRAL EXPRESSION CASSETTES ENCODING HUMAN IMMUNODEFICIENCY VIRUS ENVELOPE GLYCOPROTEINS [patent_app_type] => utility [patent_app_number] => 15/672108 [patent_app_country] => US [patent_app_date] => 2017-08-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10759 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15672108 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13065447 [patent_doc_number] => 10053496 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-08-21 [patent_title] => Compositions and methods for exosome targeted expression [patent_app_type] => utility [patent_app_number] => 15/660572 [patent_app_country] => US [patent_app_date] => 2017-07-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 25 [patent_no_of_words] => 13519 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 57 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15660572 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12769975 [patent_doc_number] => 20180148493 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-05-31 [patent_title] => HIV VPR-SPECIFIC T-CELL RECEPTORS [patent_app_type] => utility [patent_app_number] => 15/659612 [patent_app_country] => US [patent_app_date] => 2017-07-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9151 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15659612 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15225119 [patent_doc_number] => 10500264 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-12-10 [patent_title] => Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses [patent_app_type] => utility [patent_app_number] => 15/650482 [patent_app_country] => US [patent_app_date] => 2017-07-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 16 [patent_no_of_words] => 43940 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 53 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15650482 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17633910 [patent_doc_number] => 11344615 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-05-31 [patent_title] => Nucleic acids encoding chimeric dengue/Zika viruses optimized for growth and stability in vero cells [patent_app_type] => utility [patent_app_number] => 16/316005 [patent_app_country] => US [patent_app_date] => 2017-07-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 4 [patent_no_of_words] => 14269 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 350 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16316005 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15631985 [patent_doc_number] => 10588960 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-03-17 [patent_title] => Liposome-peptide conjugate and method of using same to induce production of anti-HIV antibodies [patent_app_type] => utility [patent_app_number] => 15/633487 [patent_app_country] => US [patent_app_date] => 2017-06-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 32 [patent_no_of_words] => 8659 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 90 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15633487 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16696696 [patent_doc_number] => 10947277 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-03-16 [patent_title] => Nucleic acids encoding zika virus-like particles and their use in zika virus vaccines and diagnostic assays [patent_app_type] => utility [patent_app_number] => 16/309288 [patent_app_country] => US [patent_app_date] => 2017-06-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 18 [patent_no_of_words] => 16237 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 55 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16309288 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13026457 [patent_doc_number] => 10035844 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-07-31 [patent_title] => Broadly neutralizing HIV-1 VRC07 antibodies that bind to the CD4-binding site of the envelope protein [patent_app_type] => utility [patent_app_number] => 15/612846 [patent_app_country] => US [patent_app_date] => 2017-06-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 87 [patent_figures_cnt] => 88 [patent_no_of_words] => 66398 [patent_no_of_claims] => 32 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 104 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15612846 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14929885 [patent_doc_number] => 20190300580 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-03 [patent_title] => VARIANT FLAVIVIRUS ENVELOPE SEQUENCES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/303588 [patent_app_country] => US [patent_app_date] => 2017-05-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22884 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -30 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16303588 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11954738 [patent_doc_number] => 20170258890 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-09-14 [patent_title] => 'GENETICALLY STABLE REPLICATION COMPETENT SENDAI VIRUS VECTOR(S) CONTAINING AND EXPRESSING OPTIMIZED HIV GENES' [patent_app_type] => utility [patent_app_number] => 15/498554 [patent_app_country] => US [patent_app_date] => 2017-04-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 66 [patent_figures_cnt] => 66 [patent_no_of_words] => 20701 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15498554 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14665053 [patent_doc_number] => 10370417 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-08-06 [patent_title] => Methods for the diagnosis of cancer through detection of human endogenous retrovirus WL (HERV-WL) envelope expression [patent_app_type] => utility [patent_app_number] => 15/495627 [patent_app_country] => US [patent_app_date] => 2017-04-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 14800 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 163 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15495627 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16954932 [patent_doc_number] => 11058760 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-07-13 [patent_title] => N-antigenic form poliovirus virus-like particles comprising thermostable mutations [patent_app_type] => utility [patent_app_number] => 16/094504 [patent_app_country] => US [patent_app_date] => 2017-04-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 12 [patent_no_of_words] => 14011 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 35 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16094504 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15264857 [patent_doc_number] => 20190381162 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-19 [patent_title] => PAN FILOVIRUS VACCINE COMPOSITIONS AND METHODS OF MAKING [patent_app_type] => utility [patent_app_number] => 16/084151 [patent_app_country] => US [patent_app_date] => 2017-03-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25127 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16084151 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15264857 [patent_doc_number] => 20190381162 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-19 [patent_title] => PAN FILOVIRUS VACCINE COMPOSITIONS AND METHODS OF MAKING [patent_app_type] => utility [patent_app_number] => 16/084151 [patent_app_country] => US [patent_app_date] => 2017-03-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25127 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16084151 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14158745 [patent_doc_number] => 20190106475 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-04-11 [patent_title] => T CELL RECEPTORS [patent_app_type] => utility [patent_app_number] => 16/087041 [patent_app_country] => US [patent_app_date] => 2017-03-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10624 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16087041 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14099293 [patent_doc_number] => 20190091322 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-03-28 [patent_title] => DNA ANTIBODY CONSTRUCTS AND METHOD OF USING SAME [patent_app_type] => utility [patent_app_number] => 16/087146 [patent_app_country] => US [patent_app_date] => 2017-03-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 47407 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16087146 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11756083 [patent_doc_number] => 20170202950 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-07-20 [patent_title] => 'HIGHLY IMMUNOGENIC HIV P24 SEQUENCES' [patent_app_type] => utility [patent_app_number] => 15/463176 [patent_app_country] => US [patent_app_date] => 2017-03-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 15481 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15463176 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11730558 [patent_doc_number] => 20170192001 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-07-06 [patent_title] => 'METHODS AND KITS FOR QUANTIFYING THE REMOVAL OF MOCK VIRUS PARTICLES FROM A PURIFIED SOLUTION' [patent_app_type] => utility [patent_app_number] => 15/456487 [patent_app_country] => US [patent_app_date] => 2017-03-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 12472 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15456487 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13986503 [patent_doc_number] => 20190062409 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-02-28 [patent_title] => USE OF MODIFIED HIV-1 FOR GENERATING FULLY HUMAN ANTIBODIES [patent_app_type] => utility [patent_app_number] => 16/073472 [patent_app_country] => US [patent_app_date] => 2017-03-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11181 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -48 [patent_words_short_claim] => 41 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16073472 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16743280 [patent_doc_number] => 10968255 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-04-06 [patent_title] => Compositions comprising HIV envelopes to induce CH235 lineage antibodies [patent_app_type] => utility [patent_app_number] => 16/081581 [patent_app_country] => US [patent_app_date] => 2017-03-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 334 [patent_figures_cnt] => 123 [patent_no_of_words] => 40542 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 48 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16081581 [rel_patent_id] =>[rel_patent_doc_number] =>)